Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ

T2T in #gout w serum #uric #acid / #urate target SAVES LIVES Study of achievement of target 🎯 ⬇️CVE and death If not achieving Urate <360 T2T also reduced baseline #SUA #EULAR2025 @rheumnow abst#OP0005 https://t.co/ePchJ4vqnU

• https://x.com/Janetbirdope/status/1932879622661693936/photo/1

#Oninutuzumab works in #lupus #nephritis #LN no matter how you vary the #renal #responses Of various definitions of #Complete & #Partial #renal #responses abst#OP0006 #EULAR25 @eular_org @RheumNow Not surprised 😲 https://t.co/Zn2lXkddez

• https://x.com/Janetbirdope/status/1932879643616456951/photo/1
• https://x.com/Janetbirdope/status/1932879643616456951/photo/1

1 shot will do! #symptomatic #Knee #OA given #gene #therapy #intra-#articular Seemed to last up to 104 weeks! But no placebo small safety study but sustained #WOMAC responses Needs large #RCT but v interesting #EULAR2025 @RheumNow @eular_org Abst# POS0492 https://t.co/hqTqBorrbA

• https://x.com/Janetbirdope/status/1932879669746876601/photo/1
• https://x.com/Janetbirdope/status/1932879669746876601/photo/1

Exciting results from ARGO trial: -Phase 2 of Sonelokimab (dual IL-17A-IL17F) nanobody in PsA. -Met primary endpoint of ACR50 at week 12 vs PBO. -62% achieved MDA -48% achieved composite of ACR 70+PASI 100 Looking forward to phase 3 results!!! Abstract #OP0096 #EULAR2025 https://t.co/1D52eG8ReS

• https://x.com/AdelaCastro222/status/1932899283579383966/photo/1
• https://x.com/AdelaCastro222/status/1932899283579383966/photo/1
• https://x.com/AdelaCastro222/status/1932899283579383966/photo/1

Insights from the Gut-Joint Axis in axSpA: Findings from the DESIR cohort -Baseline biomarkers of bacterial translocation: PLTP (phospholipid transfer protein) and LPS evaluated. -In early axSpA baseline PLTP activity was associated with sacroiliac radiographic progression at 5

So much needed in SLE and pregnancy 1. Risk stratification at diagnosis 2. Pregnancy counseling at dx and >1 y before pregnancy 3. Close collab with GYN necessary 4. Challenging management given gaps in evidence. #EULAR2025 #asktheexpert @RheumNow https://t.co/MXGkKpl452

• https://x.com/AdelaCastro222/status/1932909268208124100/photo/1
• https://x.com/AdelaCastro222/status/1932909268208124100/photo/1

Secukinumab for PMR? -post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed: -Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo. -Safety profile was similar to the overall GCA study

Biomarker data suggest TNFi non-responders in PsA exhibit upregulation of IL-17F gene signatures after treatment failure. Supports IL-17A/F blockade rationale with bimekizumab in TNFi-experienced patients Abstract#OP0091 @RheumNow . #EULAR2025 https://t.co/CWR6ArDRRW

• https://x.com/synovialjoints/status/1932912825858429121/photo/1

Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i: •Most common: IL-17i + TYK2i •Total exposure: 8.5–10.5 pt-years •Only mild URIs/stomatitis •Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE

• https://x.com/synovialjoints/status/1932914389482401852/photo/1

SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks: •Early TNFi: 3.7 •Combo csDMARDs: 4.1 •Step-up csDMARDs: 4.7 Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2

• https://x.com/synovialjoints/status/1932915635928940957/photo/1

Precision immunotherapy in axial spondyloarthritis: TRBV9xCD3 bispecific antibodies selectively depleted autoreactive TRBV9+ T cells from HLA-B27+ AS patient samples while sparing over 95 percent of the T cell repertoire. TRBV9xCD3 bispecific antibodies selectively depleted https://t.co/8UXqEaDYnS

• https://x.com/synovialjoints/status/1932917464574406770/photo/1

In vitro, balinatunfib (TNFR1-selective inhibitor) preserved Treg expansion in CD4+ T cells co-cultured with IL-2 and memTNF (Treg 8.99 percent, p<0.0001), unlike adalimumab and etanercept which reduced Tregs by 27.5 to 41 percent. Confirms TNFR2 sparing with selective TNFR1 https://t.co/xaczz87Xrd

• https://x.com/synovialjoints/status/1932918407331979266/photo/1

Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17, M-CSF induced hepcidin via JAK-STAT pathway. Hepcidin reduced osteoclastogenesis but correlated with synovial neutrophils and CXCL1 induction. Functional dual https://t.co/ZjUtTYPre8

• https://x.com/synovialjoints/status/1932919681989443588/photo/1

VEGF-Grab (PB101/PB102), dual VEGF/PlGF decoy receptor, inhibited angiogenesis, RA-FLS invasion, and Th17 cell differentiation in RA and MS models. PB102 reduced IL-17 and GM-CSF co-expressing Th17 cells, suppressed pannus and joint destruction in CIA, and outperformed IFN-β in https://t.co/qhVRYT4RbK

• https://x.com/synovialjoints/status/1932920559576232224/photo/1